Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low‐dose‐rate brachytherapy for localized prostate cancer

Higher quality of postimplant dosimetric evaluation is associated with higher biochemical recurrence-free survival rates after low-dose-rate brachytherapy for localized prostate cancer. Postimplant prostate D90 is a key dosimetric parameter showing the quality of low-dose-rate brachytherapy. In this study, to improve the quality of low-dose-rate brachytherapy for localized prostate cancer, we investigated pre-implant factors affecting the...